RepligenRGEN
About: Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category and was 58% of 2024 revenue, while chromatography, proteins, and process analytics were 19%, 12%, and 9%, respectively. Customers in North America, Europe, and Asia Pacific contributed 44%, 37%, and 19% of revenue, respectively.
Employees: 1,778
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
38% more first-time investments, than exits
New positions opened: 62 | Existing positions closed: 45
29% more repeat investments, than reductions
Existing positions increased: 168 | Existing positions reduced: 130
2% more funds holding
Funds holding: 429 [Q4 2024] → 439 (+10) [Q1 2025]
1.43% more ownership
Funds ownership: 100.37% [Q4 2024] → 101.8% (+1.43%) [Q1 2025]
0% more funds holding in top 10
Funds holding in top 10: 1 [Q4 2024] → 1 (+0) [Q1 2025]
10% less capital invested
Capital invested by funds: $8.09B [Q4 2024] → $7.31B (-$782M) [Q1 2025]
84% less call options, than puts
Call options by funds: $11M | Put options by funds: $68.6M
Research analyst outlook
6 Wall Street Analysts provided 1 year price targets over the past 3 months
6 analyst ratings
RBC Capital Conor McNamara | 66%upside $204 | Outperform Maintained | 30 Jul 2025 |
Wells Fargo Brandon Couillard | 42%upside $175 | Overweight Maintained | 30 Jul 2025 |
Stephens & Co. Steven Etoch | 30%upside $160 | Overweight Assumed | 22 Jul 2025 |
Evercore ISI Group Daniel Markowitz | 6%upside $130 | In-Line Maintained | 8 Jul 2025 |
Barclays Luke Sergott | 22%upside $150 | Overweight Initiated | 24 Jun 2025 |
Financial journalist opinion
Based on 5 articles about RGEN published over the past 30 days
